Alkem Laboratories Limited secures 51% stake in Saudi JV

Alkem incorporated Alkem Pharma on 8 November 2026 with a 51% stake, subscribing SAR 38.25 lakh in cash for 38,250 shares in the Saudi limited liability joint venture. The new entity is intended to manufacture, import, market and distribute pharmaceutical and nutraceutical products in the Kingdom of Saudi Arabia.

What did Alkem incorporate in Saudi Arabia?

Alkem incorporated Alkem Pharma, a limited liability company and joint-venture subsidiary, in the Kingdom of Saudi Arabia on 8 November 2026. The filing describes the entity as a vehicle for pharmaceutical and nutraceutical activities rather than reporting it as an operating business with existing turnover.

The incorporation followed Alkem's earlier disclosures of 12 August 2025 and 13 February 2026 concerning a shareholders' agreement for a Saudi joint-venture subsidiary. The 8 November 2026 announcement confirms that the legal entity contemplated under that agreement has now been established as Alkem Pharma.

Alkem reported the development under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The disclosure identifies Alkem Pharma as a subsidiary in the form of a joint venture, with total capital of SAR 75 lakh.

How much of Alkem Pharma does Alkem own?

Alkem owns 51% of Alkem Pharma's total share capital after subscribing for 38,250 shares at SAR 100 each for SAR 38.25 lakh in cash. The subscription gives Alkem more than half of the Saudi venture's 75,000 shares, while the filing does not identify the holder or holders of the remaining 49%.

Alkem Pharma's SAR 75 lakh capital is divided into 75,000 shares with a face value of SAR 100 each. Alkem's 38,250 shares equal 51% of that total, matching the ownership percentage reported in the annexure to the 8 November 2026 filing.

The consideration was cash, not a share swap or another specified form of payment. The filing does not disclose any additional funding commitment beyond the SAR 38.25 lakh share subscription, nor does it set out rights attached to the shares or governance arrangements for the joint venture.

What business will Alkem Pharma conduct in Saudi Arabia?

Alkem Pharma will be involved in the manufacture, import, marketing and distribution of pharmaceutical and/or nutraceutical products within Saudi Arabia. The filing places the venture in the pharmaceuticals and nutraceuticals industry and names four operating activities, covering local production as well as bringing products into the country and selling them.

The disclosure does not name any products, brands, therapy areas, manufacturing facility or distribution channel. It also gives no date for the start of manufacturing, import, marketing or distribution, despite the entity having been incorporated on 8 November 2026.

Turnover is listed as not applicable in the disclosure. This means Alkem did not report sales or a three-year turnover record for Alkem Pharma, and the announcement does not provide a revenue, output or distribution-coverage target for the Saudi business.

Why did Alkem make the Saudi investment?

Alkem said the investment is strategic and is intended to expand its business and market reach in the Kingdom of Saudi Arabia. The stated purpose links the SAR 38.25 lakh cash subscription and 51% holding to geographic expansion, but the filing does not quantify expected sales, market share, capacity or profitability.

The filing says the acquisition is not a related-party transaction. It also says that no promoter, promoter group or group company has an interest in Alkem Pharma, distinguishing the SAR 38.25 lakh subscription from a transaction involving those parties.

Alkem reported that governmental or regulatory approvals required for the acquisition were not applicable. It also marked the indicative time period for completion as not applicable, consistent with the incorporation of Alkem Pharma having already occurred on 8 November 2026.

What remains undisclosed about the Saudi joint venture?

Alkem has not disclosed the identity of its joint-venture partner, the partner's shareholding, or the partner's capital contribution to Alkem Pharma. The filing only establishes that Alkem holds 51% of the SAR 75 lakh capital, leaving the ownership and role of the remaining 49% undisclosed.

The announcement also does not disclose board appointments, management personnel, manufacturing assets, product-registration plans or launch milestones. While the entity may manufacture, import, market and distribute pharmaceutical and nutraceutical products, no allocation of the SAR 75 lakh capital among these activities is provided.

Alkem has disclosed no financial objective for the vehicle beyond the strategic aim of expanding market reach in Saudi Arabia. As turnover is not applicable and no forecast is supplied, the filing does not allow a comparison between projected commercial activity and Alkem Pharma's initial SAR 75 lakh capitalisation.

Conclusion

The incorporation of Alkem Pharma on 8 November 2026 turns Alkem's previously disclosed Saudi joint-venture plan into an incorporated limited liability company. Alkem has subscribed SAR 38.25 lakh in cash for 38,250 shares and a 51% stake in an entity capitalised at SAR 75 lakh, with a mandate spanning pharmaceutical and nutraceutical manufacture, import, marketing and distribution.

The next disclosures to watch are any plans for products, operating commencement, manufacturing or import arrangements, and details of the undisclosed joint-venture partner. Alkem has not provided a launch schedule, financial target or turnover figure, so subsequent information on commercial activity would show how the Saudi entity advances the stated market-reach objective.